triple glp 1 agonist GLP-1 Orals and Multi-Agonists: Advancing Next-Gen Weight Loss Therapies with Humanized Models New strategies for the treatment

In crude analyses, GLP-1 receptor agonist use was associated with an increased incidence of suicidality compared with DPP-4 inhibitors (crude incidence rates 3.9 v 1.8 per 1000 person years, respectively

Constipation occurs in

95% CI 0.90, 1.01) and cerebrovascular events (HR 0.99

These drugs effectively lower blood glucose levels and provide cardiovascular and renal benefits, making them a preferred treatment option in diabetes care

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

FDA approves Jardiance (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease